News and Trends 15 Aug 2022Aptinyx fibromyalgia drug misses endpoint Biopharma company Aptinyx Inc. says its phase 2b clinical study evaluating the effects of NYX-2925 in patients with fibromyalgia did… August 15, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email